Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) will participate in the 2022 Wells Fargo Securities Healthcare Conference on September 8, 2022, at 2:35 p.m. Eastern Time. Representing the company will be Glenn Boehnlein, CFO, and Jason Beach, VP of Investor Relations. A simultaneous webcast of the presentation will be available on Stryker's website, where it will be archived for later access. Stryker is recognized as a leading medical technology company, impacting over 100 million patients annually through its innovative products and services.
Stryker (NYSE:SYK) announced a quarterly dividend of $0.695 per share, payable on October 31, 2022, to shareholders of record by September 30, 2022. This marks a 10.3% increase compared to the previous year, while remaining unchanged from the last quarter. Stryker, a leader in medical technology, aims to enhance healthcare outcomes with innovative products and services across various fields, impacting over 100 million patients globally each year.
Stryker (NYSE:SYK) reported second quarter 2022 results showcasing a 4.6% increase in net sales to $4.5 billion and a 6.1% organic net sales growth. The reported operating income margin was 17.2%, while adjusted operating income margin contracted by 220 basis points to 23.7%. Reported EPS rose 11.0% to $1.72, with adjusted EPS of $2.25 remaining stable compared to 2021. Despite supply chain challenges, Stryker anticipates full-year organic net sales growth of 8% to 9%, although foreign exchange impacts may negatively affect earnings.
Stryker (NYSE:SYK) has announced a conference call set for July 26, 2022, at 4:30 p.m. Eastern Time to discuss its operational results for Q2 2022 and provide updates. The final results will be released at 4:05 p.m. that day. Interested participants can register for the call via Stryker's website. A simultaneous webcast will be available, and a replay can be accessed afterwards. Stryker, a leading medical technology firm, focuses on enhancing healthcare outcomes through innovative products in various medical sectors.
Stryker (NYSE:SYK) has launched an experiential campaign in four major U.S. cities—New York, Los Angeles, Chicago, and Miami—beginning June 27 to raise awareness about bunions and treatment options. The campaign features interactive sidewalk chalk designs that encourage foot traffic to visit FreeYourFeet.org for educational resources. Bunions affect one in three Americans annually, and Stryker aims to inform patients about minimally invasive surgical options for relief. The initiative runs until September 29, focusing on improving patient outcomes.
Stryker (NYSE:SYK) participated for the first time as a strategic partner at the 6th World Intelligence Congress (WIC) in China, showcasing its Advanced Digital Healthcare solutions. With over 200 million people aged 65 and above in China, there is a growing demand for health technologies. Stryker's Digital, Robotics, and Enabling Technologies (DRE) aims to enhance patient care outcomes through digital capabilities. The company's Mako SmartRobotics™ technology is highlighted, poised to improve surgical precision and efficiency, further enhancing healthcare availability in China.
Stryker has received 510(k) clearance from the U.S. Food and Drug Administration for its Q Guidance System. This advanced planning and intraoperative guidance system is designed for spine surgery, enabling both open and percutaneous procedures. The system features innovative software, versatile tracking options, and high-performance navigation technology. Notably, the Spine Guidance Software is the first of its kind cleared for use in pediatric patients aged 13 and older. Stryker aims to provide a comprehensive surgical platform across multiple specialties.
Stryker (NYSE:SYK) has launched the EasyFuse™ Dynamic Compression System, a new foot and ankle staple made from nitinol, known for its strength and shape recovery. This system aims to enhance surgical efficiency by simplifying procedures and reducing waste in operating rooms. The EasyFuse system features an extra wide staple bridge for consistent strength, universal sterile instrumentation to cut down on complexity, and an intuitive inserter for easy deployment. This innovation is expected to improve patient outcomes and expand options for surgeons.
Stryker (NYSE:SYK) has announced the appointment of Jason Beach as the new Vice President of Investor Relations, effective July 1, 2022. Beach, who joined Stryker in 2018, previously held the role of Vice President of Finance in the Instruments division, where he contributed to significant growth and successful acquisitions. He will report to Glenn Boehnlein, the Chief Financial Officer. Meanwhile, Preston Wells will transition to Vice President, Group Chief Financial Officer for Orthopaedics and Spine. This move is part of Stryker's strategy to enhance its investor relations capabilities.
Stryker (NYSE: SYK) announced leadership changes on May 4, 2022, with Sherilyn S. McCoy named as the new Lead Independent Director, replacing Allan C. Golston. McCoy joined the board in 2018, previously chairing the Governance and Nominating Committee since 2019. Golston, a board member since 2011, has served as Lead Independent Director since 2016. Mary K. Brainerd will replace McCoy as Chair of the Governance and Nominating Committee. Stryker emphasizes diversity and effective governance, supporting better healthcare outcomes.